Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282463 · ClinicalTrials.gov registry record · Phase 2
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT01282463 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 148 participants.
The verdict
NCT01282463, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and icrucumab.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Ramucirumab DP
- BIOLOGICAL Icrucumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2011-04 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282463
The ClinicalTrials.gov registry entry for NCT01282463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01282463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282463 about?
NCT01282463 is a clinical study titled "Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma". This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docet...
What is the current status of trial NCT01282463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2011-04. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01282463?
The interventions under investigation include: Docetaxel (DRUG), Ramucirumab DP (BIOLOGICAL), Icrucumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01282463?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.